AXA Pharma has entered into a clinical partnership with AstraZeneca Blood Research and Development Excellence to explore a combination of Bcl-2 inhibitors and BTK inhibitors.

is a clinical research and development company dedicated to the development of innovative drugs in the treatment of cancer, hepatitis B and aging-related diseases - AXA Pharmaceuticals (6855HK) today announced that it has established a clinical research partnership with AstraZeneca (LSE/STO/NYSE: AZN) In the Center for Blood Research Excellence (Acerta Pharma)Suzhou, China, And Rockville, Maryland, USA, June 22, 2020 /PRNewswire/ -- AXA Pharmaceuticals (6855HK) today announced that it has established a clinical research partnership with AstraZeneca (LSE/STO/NYSE: AZN) In the Center for Blood Research Excellence (Acerta Pharma)The two sides will conduct clinical studies on the combination of APG-2 selective inhibitor APG-2575 and Acerta's BTK (Bruton tyrosine protein kinet) inhibitor CALQUENCE®
(acalabrutinib) in The Research Site to evaluate the combination of the drug in relapsed chronic lymphocytic leukemia/small lymphocyte lymphoma (Chronic Lymphocythe global multi-center, open Ib/II dose efficacy exploration study, which aims to assess the safety, tolerance, and initial evaluation of the effectiveness of APG-2575 monodrug or joint CALQUENCE®
treating patients with relapsed cLL/SLLThe pilot program is being launched in the United States, Europe and Australia, and the first patient administration has been completed in the United StatesCLL/SLL is a mature B lymphocyte clone proliferation tumor, is the highest incidence of adult leukemia in developed countries in Europe and the United States, accounting for about 30% of all leukemia, the annual incidence of 2-6/100,000 people, 65 years of age up to 12.8/100,000 peopleAlthough the first-line solution significantly improves the initial treatment and remission rate of CLL/SLL patients, but the need for long-term medication to control the disease, once relapsed often the prognosis is very poorRecent research has found that BTK inhibitors in combination with Bcl-2 inhibitors treatment CLL/SLL has the advantage of high depth response rate, and may even become long-term treatment for limited cycle therapy, for CLL/SLL patients clinical cure and discontinuation of the possibleThis also provides the basis for the joint drug use exploration of APG-2575 and BTK inhibitors"We are pleased to have reached this clinical partnership with AstraZeneca's Acerta," said DrDajun Yang, Chairman and CEO of aAxaPharmaceuticalAPG-2575 is an important research variety of AXA pharmaceutical apoptosis product pipeline, which shows great potential in the treatment of malignant tumors in the blood systemThis partnership will accelerate clinical development of aPG-2575 worldwideSafe and effective combination drug use is an important trend in tumor treatment, and the potential of Bcl-2 inhibitors and BTK inhibitors cannot be ignoredWe look forward to the potential synergies between APG-2575 and CALQUENCE®
treatment to provide more treatment possibilities for CLL/SLL patients worldwide"
References
N Engl J Med 2019;380:2095-2103.
Wiestner AIbrutinib and venetoclax - doubling down on CLLN Engl J Med 2019;380:2169-2171.
AboutAPG-2575
APG-2575 is a new oral Bcl-2 selective inhibitor in the research of AXA Pharmaceuticals, which restores the procedural death mechanism of tumor cells (cell apoptosis) by selectively inhibiting Bcl-2 protein family members, thereby killing tumors and to be used to treat a variety of blood malignancies Previously, the company has been in the United States, Australia, China to launch the drug's single drug Phase I clinical trials Since March this year, APG-2575 has been approved for a number of Ib/II clinical trials in the United States and China, and is simultaneously advancing the clinical development of multiple blood tumor indications on AXA Pharmaceuticals AXA Pharmaceuticals is a China-based, global-oriented clinical development phase of the original new drug research and development enterprises, committed to the development of cancer, hepatitis B and aging-related diseases and other therapeutic areas of innovative drugs On October 28, 2019, AXA Pharmaceuticals was listed on the Main Board of the Hong Kong Stock Exchange under the stock code: 6855 HK AsiaSa Pharma has an independently constructed protein-protein interaction target drug design platform, which is at the forefront of the research and development of new drugs in the apoptosis pathway world The company has established eight small molecule new drug product lines that have entered the clinical development phase, including inhibitors that inhibit key proteins in the path of apoptosis such as Bcl-2, IAP, or MDM2-p53, and a new generation of inhibitors for kinase mutants that appear in cancer treatment, making it the only innovative company in the world that has a clinicaldevelopment of apoptosis-path key proteins More than 30 Phase I/II clinical trials are being conducted in China, the United States and Australia HQP1351, the core species for the treatment of drug-resistant chronic myeloid leukemia, has been certified by the FDA for fast-track and orphan drugs, and has submitted a new drug listing application in China forward-looking statements
forward-looking statements made herein only in connection with the events or materials made at the time of this statement Except as required by law, we are not responsible for updating or publicly modifying any forward-looking statements or unforeseen events after the date of making the forward-looking statements, whether or not new information, future events or otherwise Please review this article and understand that our actual future performance or performance may differ materially from expectations All statements made in this article are made on the date of publication of this article and may be subject to change in future developments .